VCYT Looks 5.7% Overvalued on GF Value™ After Convergent Genomics Acquisition

gurufocus.com · 2026-09-14

On September 14, 2026, Veracyte Inc (NASDAQ: VCYT) announced its acquisition of Convergent Genomics, integrating the UroAmp platform into its diagnostic portfol

TickrTrends take: VCYT is currently assessed as fairly valued by TickrTrends, which provides a neutral baseline for evaluating the company's recent acquisition of Convergent Genomics. The GF Value analysis suggesting overvaluation presents a divergence from the fairly valued verdict, indicating that different valuation methodologies are reaching different conclusions about the stock's current price. Healthcare investors monitoring this stock should track whether the market reprices VCYT as it integrates the acquisition and whether the company's financial performance supports the current valuation levels over the coming quarters.

Read the full story at gurufocus.com →